



University of Groningen

In HF with mitral regurgitation, adding transcatheter mitral valve repair to medical therapy improved renal outcomes at 2 $\rm y$

Damman, Kevin; Van Spall, Harriette G. C.

Published in: Annals of Internal Medicine

DOI: 10.7326/J22-0037

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version Publisher's PDF, also known as Version of record

Publication date: 2022

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA): Damman, K., & Van Spall, H. G. C. (2022). In HF with mitral regurgitation, adding transcatheter mitral valve repair to medical therapy improved renal outcomes at 2 y. *Annals of Internal Medicine*, *43*, 1639-1648. https://doi.org/10.7326/J22-0037

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: https://www.rug.nl/library/open-access/self-archiving-pure/taverneamendment.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

C ★★★★★☆☆

In HF with mitral regurgitation, adding transcatheter mitral valve repair to medical therapy improved renal outcomes at 2 y

Beohar N, Ailawadi G, Kotinkaduwa LN, et al. Impact of baseline renal dysfunction on cardiac outcomes and end-stage renal disease in heart failure patients with mitral regurgitation: the COAPT trial. Eur Heart J. 2022;43:1639-48.

- **Questions:** In patients with heart failure (HF) and severe secondary mitral regurgitation (MR), does adding transcatheter mitral valve repair (TMVR) to medical therapy improve renal outcomes? Does treatment effect vary by baseline renal function?
- **Design:** Post hoc analysis of a randomized controlled trial (COAPT [Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation]).
- Blinding: Treatment allocation concealed; unblinded.*†
- Setting: 78 centers in Canada and the USA.*

Patients: 614 patients (mean age, 72 y; 64% men) who had HF; left ventricular ejection fraction, 20% to 50%; left ventricular end-systolic

diameter \leq 70 mm; moderate-to-severe (grade 3+) or severe (grade 4+) secondary MR; and ongoing symptoms despite maximally tolerated, guide-line-directed medical therapy (GDMT). Key exclusions: severe pulmonary hypertension or symptomatic moderate or severe right ventricular dysfunction.

R Inte

Interventions: TMVR, using the MitraClip device, plus GDMT (n = 302)*, or GDMT alone (n = 312)*.

Funding: Abbott.

*Some information from Stone GW, Lindenfeld J, Abraham WT, et al. Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med. 2018;379:2307-18. †See Glossary.

Results: TMVR + GDMT vs. GDMT alone in HF with moderate-to-severe or severe secondary MR (intention-to-treat analysis)

Outcomes	Renal dysfunction subgroups (n)‡	Event rates		At 2 y	
		TMVR + GDMT	GDMT alone	RRR (95% CI)§	NNT (CI)§
New-onset ESRD	All (569)¶	2.9%	8.1%	65% (23 to 84)	19 (15 to 54)
New renal replacement therapy	All (574)¶	2.5%	7.4%	66% (21 to 86)	21 (16 to 64)
Death or HF hospitalization**	No dysfunction (139)	33%	58%	42% (14 to 63)	5 (3 to 12)
	Moderate (323)	44%	65%	32% (15 to 45)	5 (4 to 11)
	Severe (144)	61%	77%	20% (0 to 38)	Not significant

Bottom line:

In HF with moderate-tosevere or severe secondary MR, adding TMVR to GDMT reduced new-onset end-stage renal disease and new renal replacement therapy at 2 years.

eGFR = estimated glomerular filtration rate; ESRD = end-stage renal disease; GDMT = guideline-directed medical therapy; HF = heart failure; MR = mitral regurgitation; TMVR = transcatheter mitral valve repair; other abbreviations defined in Glossary. Primary outcome indicated by boldface.

 \pm No renal dysfunction = eGFR \geq 60 mL/min/1.73 m²; moderate: eGFR = 30 to <60 mL/min/1.73 m²; severe: eGFR <30 mL/min/1.73 m².

§RRR, NNT, and CI calculated using GDMT event rates and hazard ratios in article.

||eGFR <15 mL/min/1.73 m² or renal replacement therapy.

¶Analysis excludes patients with condition at baseline.

**Post hoc analysis by renal dysfunction subgroup: treatment-subgroup interaction, P = 0.62.

Commentary: TMVR improves outcomes in HF with reduced ejection fraction (HFrEF) and moderate-to-severe or worse MR, but whether it does so in the setting of renal dysfunction is unknown. Patients with HFrEF often have renal dysfunction, which is associated with adverse outcomes. Neurohormonal and hemodynamic changes that cause congestion in HFrEF also impair renal function through increased renal venous pressure and progressive renal hypoperfusion (1). In clinical settings, renal dysfunction often limits use of life-saving GDMT in HFrEF and interventions requiring contrast.

In Beohar and colleagues' analysis of the COAPT trial, patients with HFrEF and at least moderate-to-severe MR had evidence of congestion, including limiting symptoms, markedly elevated N-terminal pro-B-type natriuretic peptide levels, and increased pulmonary pressures. The congestive state translated to a low estimated glomerular filtration rate (eGFR) at baseline for most patients; >75% had moderate or severe renal dysfunction.

Patients receiving GDMT alone had high 2-year risk for the composite of death or HF hospitalization, which was progressively more frequent with worsening renal function. TMVR reduced the incidence of renal replacement therapy, end-stage renal disease, and regardless of baseline renal function, the composite of death or HF hospitalization. These findings were consistent with data from nonrandomized registries, which showed an association between TMVR and improved eGFR at short- and long-term follow-up (2). Strong evidence for the effect of conventional mitral valve repair on renal function and renal outcomes is lacking.

This article was published at Annals.org on 7 June 2022. doi:10.7326/J22-0037

TMVR may improve forward cardiac output, congestion, and renal perfusion, thereby improving cardiovascular and renal outcomes. In the context of positive primary COAPT results in patients with HFrEF and at least moderateto-severe MR, Beohar and colleagues' analysis shows that reduced eGFR portends a poor prognosis that may be improved with TMVR.

Kevin Damman, MD, PhD

University of Groningen and University Medical Center Groningen Groningen, The Netherlands

Harriette G.C. Van Spall, MD, MPH

McMaster University Hamilton, Ontario, Canada

Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum= J22-0037.

References

- Beldhuis IE, Lam CS, Testani JM, et al. Evidence-based medical therapy in patients with heart failure with reduced ejection fraction and chronic kidney disease. Circulation. 2022;145:693-712
- Lo KB, Dayanand S, Ram P, et al. Interrelationship between kidney function and percutaneous mitral valve interventions: a comprehensive review. Curr Cardiol Rev. 2019;15:76-82.

ACP Journal Club is editorially independent from Annals of Internal Medicine.